Difference between revisions of "Migden MR, et al. N. Engl. J. Med. (2018) cited as Ref 638 in DOI: 10.1038/s41392-020-0110-5 (Q9901)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 379, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma (English) | ||
| Property / title: PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:05, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Migden MR, et al. N. Engl. J. Med. (2018) cited as Ref 638 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Migden MR
0 references
2018
0 references
N. Engl. J. Med.
0 references
379
0 references
PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma (English)
0 references
